These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14645013)

  • 1. Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels.
    Sim DS; Merrill-Skoloff G; Furie BC; Furie B; Flaumenhaft R
    Blood; 2004 Mar; 103(6):2127-34. PubMed ID: 14645013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
    Zhang W; Colman RW
    Blood; 2007 Sep; 110(5):1475-82. PubMed ID: 17392505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
    Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity.
    Proença-Ferreira R; Franco-Penteado CF; Traina F; Saad ST; Costa FF; Conran N
    Br J Haematol; 2010 Apr; 149(2):280-8. PubMed ID: 20136824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.
    Minami N; Suzuki Y; Yamamoto M; Kihira H; Imai E; Wada H; Kimura Y; Ikeda Y; Shiku H; Nishikawa M
    Life Sci; 1997; 61(25):PL 383-9. PubMed ID: 9416770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions.
    Coenen DM; Heinzmann ACA; Oggero S; Albers HJ; Nagy M; Hagué P; Kuijpers MJE; Vanderwinden JM; van der Meer AD; Perretti M; Koenen RR; Cosemans JMEM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
    Zhang W; Ke H; Tretiakova AP; Jameson B; Colman RW
    Protein Sci; 2001 Aug; 10(8):1481-9. PubMed ID: 11468344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis.
    Colman RW
    Semin Thromb Hemost; 2004 Aug; 30(4):451-60. PubMed ID: 15354266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nonhydrolyzable reactive cAMP analogue, (S(p))-8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3',5'-cyclic S-(methyl)monophosphorothioate, irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase at micromolar concentrations.
    Hung SH; Madhusoodanan KS; Boyd RL; Baldwin JL; Colman RF; Colman RW
    Biochemistry; 2002 Mar; 41(9):2962-9. PubMed ID: 11863434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.
    Sun B; Li H; Shakur Y; Hensley J; Hockman S; Kambayashi J; Manganiello VC; Liu Y
    Cell Signal; 2007 Aug; 19(8):1765-71. PubMed ID: 17482796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
    Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.
    Aburima A; Berger M; Spurgeon BEJ; Webb BA; Wraith KS; Febbraio M; Poole AW; Naseem KM
    Blood; 2021 Feb; 137(5):678-689. PubMed ID: 33538796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.
    Kariyazono H; Nakamura K; Shinkawa T; Yamaguchi T; Sakata R; Yamada K
    Thromb Res; 2001 Mar; 101(6):445-53. PubMed ID: 11323002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.
    Yashiro Y; Ohhashi T
    Jpn J Physiol; 2002 Oct; 52(5):471-7. PubMed ID: 12533252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity.
    Yagi H; Yamaguchi N; Shida Y; Hayakawa M; Matsumoto M; Sugimoto M; Wada H; Tsubaki K; Fujimura Y
    Eur J Pharmacol; 2012 Sep; 691(1-3):151-5. PubMed ID: 22796451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
    Matousovic K; Tsuboi Y; Walker H; Grande JP; Dousa TP
    J Lab Clin Med; 1997 Nov; 130(5):487-95. PubMed ID: 9390636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Dunkern TR; Hatzelmann A
    Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.
    Kohda N; Tani T; Nakayama S; Adachi T; Marukawa K; Ito R; Ishida K; Matsumoto Y; Kimura Y
    Thromb Res; 1999 Nov; 96(4):261-8. PubMed ID: 10593428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells.
    Nishio Y; Kashiwagi A; Takahara N; Hidaka H; Kikkawa R
    Horm Metab Res; 1997 Oct; 29(10):491-5. PubMed ID: 9405974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.